← Russell 3000 cross-section

IMDX Insight Molecular Diagnostics Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$141m
Revenue TTM
$2m
Net income TTM
$-49m
Free cash flow
$-31m
Composite score
Sector rank
#2983

Valuation

P / E
EV / EBITDA
EV / sales
73.6
FCF yield
-21.94%
Earnings yield vs 10-yr
-39.84pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2,955.6%
EBITDA margin
-2,865.6%
ROE
231.7%
ROIC
Revenue growth
-60.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As such, we are working with these regulatory bodies to attain such clearance and approval, as applicable, supporting future distribution and higher sales of our products for clinical use. See Note 7, “Common Stock – February 2026 Offering,” to our consolidated financial statements included elsewhere in this Report for additional information. Results of Operations Summary Results of Operations Results of Operations – Three Months Ended June 30, 2026 Compared with the Three Months Ended June 30, 2025 Total net revenue decreased to $239,000 for the three months ended June 30, 2026, compared to $518,000 in the comparable prior period primarily from Laboratory Services as further discussed below …Insight Molecular Diagnostics Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →